CONMED (CNMD) 10-Q 28 Oct 21 2021 Q3 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	9 Months Ended
	Sep. 30, 2021	Oct. 25, 2021
Cover [Abstract]
Entity Registrant Name	CONMED CORPORATION
Document Quarterly Report	true
Document Type	10-Q
Document Period End Date	Sep. 30, 2021
Current Fiscal Year End Date	--12-31
Document Fiscal Period Focus	Q3
Document Fiscal Year Focus	2021
Entity File Number	001-39218
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	16-0977505
Entity Address, Address Line One	11311 Concept Blvd
Entity Address, City or Town	Largo,
Entity Address, State or Province	FL
Entity Address, Postal Zip Code	33773
City Area Code	727
Local Phone Number	392-6464
Entity Central Index Key	0000816956
Title of 12(b) Security	Common Stock, $0.01 par value
Trading Symbol	CNMD
Security Exchange Name	NYSE
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
Document Transition Report	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		29,247,120
Amendment Flag	false

Consolidated Condensed Statemen

Consolidated Condensed Statements of Comprehensive Income (Loss) (Unaudited) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Statement of Comprehensive Income [Abstract]
Net sales	$ 248,827	$ 237,835	$ 736,665	$ 609,631
Cost of sales	106,521	104,137	324,485	284,845
Gross profit	142,306	133,698	412,180	324,786
Selling and administrative expense	104,736	94,380	307,476	274,721
Research and development expense	10,859	9,936	32,203	28,756
Operating expenses	115,595	104,316	339,679	303,477
Income from operations	26,711	29,382	72,501	21,309
Interest expense	8,145	11,943	27,917	32,938
Other expense	1,127	89	1,127	266
Income (loss) before income taxes	17,439	17,350	43,457	(11,895)
Provision for income taxes	2,491	10,500	5,359	2,728
Net income (loss)	14,948	6,850	38,098	(14,623)
Comprehensive income (loss)	$ 13,756	$ 8,976	$ 42,242	$ (16,858)
Per share data:
Basic (in dollars per share)	$ 0.51	$ 0.24	$ 1.31	$ (0.51)
Diluted (in dollars per share)	$ 0.47	$ 0.23	$ 1.19	$ (0.51)
Weighted average common shares:
Basic (shares)	29,179	28,583	29,097	28,529
Diluted (shares)	32,143	29,426	32,020	28,529

Consolidated Condensed Balance

Consolidated Condensed Balance Sheets (Unaudited) - USD ($) $ in Thousands	Sep. 30, 2021	Dec. 31, 2020
Current assets:
Cash and cash equivalents	$ 31,511	$ 27,356
Accounts receivable, net	165,433	177,152
Inventories	228,572	194,868
Prepaid expenses and other current assets	17,889	17,278
Total current assets	443,405	416,654
Property, plant and equipment, net	109,181	111,407
Goodwill	617,651	618,440
Other intangible assets, net	478,861	501,537
Other assets	104,994	103,635
Total assets	1,754,092	1,751,673
Current liabilities:
Current portion of long-term debt	12,251	18,415
Accounts payable	46,596	53,310
Accrued compensation and benefits	54,632	50,171
Other current liabilities	69,713	68,305
Total current liabilities	183,192	190,201
Long-term debt	703,335	735,221
Deferred income taxes	58,940	57,875
Other long-term liabilities	52,942	59,338
Total liabilities	998,409	1,042,635
Commitments and contingencies
Shareholders' equity:
Preferred stock, par value $.01 per share; authorized 500,000 shares; none outstanding	0	0
Common stock, par value $0.01 per share; 100,000,000 shares authorized; 31,299,194 shares issued in 2021 and 2020, respectively	313	313
Paid-in capital	394,810	382,628
Retained earnings	478,035	457,417
Accumulated other comprehensive loss	(59,537)	(63,681)
Less: 2,064,390 and 2,410,045 shares of common stock in treasury, at cost in 2021 and 2020, respectively	(57,938)	(67,639)
Total shareholders’ equity	755,683	709,038
Total liabilities and shareholders’ equity	$ 1,754,092	$ 1,751,673

Consolidated Condensed Balanc_2

Consolidated Condensed Balance Sheets (Unaudited) (Parenthetical) - $ / shares	Sep. 30, 2021	Dec. 31, 2020
Statement of Financial Position [Abstract]
Preferred stock, par value (dollars per share)	$ 0.01	$ 0.01
Preferred stock, shares authorized (in shares)	500,000	500,000
Preferred stock, shares outstanding (in shares)	0	0
Common stock, par value (dollars per share)	$ 0.01	$ 0.01
Common stock, shares authorized (in shares)	100,000,000	100,000,000
Common stock, shares issued (in shares)	31,299,194	31,299,194
Treasury stock, shares (in shares)	2,064,390	2,410,045

Consolidated Condensed Statem_2

Consolidated Condensed Statements of Shareholders' Equity (Unaudited) - USD ($) shares in Thousands, $ in Thousands	Total	Common Stock	Paid-in Capital	Retained Earnings	Accumulated Other Comprehensive Loss	Treasury Stock
Balance at period start (shares) at Dec. 31, 2019		31,299
Balance at period start at Dec. 31, 2019	$ 710,467	$ 313	$ 379,324	$ 470,844	$ (59,277)	$ (80,737)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Common stock issued under employee plans	(5,040)		(7,736)			2,696
Stock-based compensation	3,032		3,032
Dividends on common stock ($0.20 per share)	(5,703)			(5,703)
Comprehensive income (loss):
Cash flow hedging gain (loss), net					2,405
Pension liability, net of income tax					535
Foreign currency translation adjustments					(9,988)
Net income (loss)				5,927
Comprehensive income (loss)	(1,121)
Balance at period end (shares) at Mar. 31, 2020		31,299
Balance at period end at Mar. 31, 2020	701,635	$ 313	374,620	471,068	(66,325)	(78,041)
Balance at period start (shares) at Dec. 31, 2019		31,299
Balance at period start at Dec. 31, 2019	710,467	$ 313	379,324	470,844	(59,277)	(80,737)
Comprehensive income (loss):
Cash flow hedging gain (loss), net	(3,050)
Pension liability, net of income tax	1,605
Foreign currency translation adjustments	(790)
Net income (loss)	(14,623)
Comprehensive income (loss)	(16,858)
Balance at period end (shares) at Sep. 30, 2020		31,299
Balance at period end at Sep. 30, 2020	683,141	$ 313	381,119	439,086	(61,512)	(75,865)
Balance at period start (shares) at Mar. 31, 2020		31,299
Balance at period start at Mar. 31, 2020	701,635	$ 313	374,620	471,068	(66,325)	(78,041)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Common stock issued under employee plans	133		(1,150)			1,283
Stock-based compensation	3,555		3,555
Dividends on common stock ($0.20 per share)	(5,712)			(5,712)
Comprehensive income (loss):
Cash flow hedging gain (loss), net					(2,429)
Pension liability, net of income tax					535
Foreign currency translation adjustments					4,581
Net income (loss)				(27,400)
Comprehensive income (loss)	(24,713)
Balance at period end (shares) at Jun. 30, 2020		31,299
Balance at period end at Jun. 30, 2020	674,898	$ 313	377,025	437,956	(63,638)	(76,758)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Common stock issued under employee plans	1,455		562			893
Stock-based compensation	3,532		3,532
Dividends on common stock ($0.20 per share)	(5,720)			(5,720)
Comprehensive income (loss):
Cash flow hedging gain (loss), net	(3,026)				(3,026)
Pension liability, net of income tax	535				535
Foreign currency translation adjustments	4,617				4,617
Net income (loss)	6,850			6,850
Comprehensive income (loss)	8,976
Balance at period end (shares) at Sep. 30, 2020		31,299
Balance at period end at Sep. 30, 2020	683,141	$ 313	381,119	439,086	(61,512)	(75,865)
Balance at period start (shares) at Dec. 31, 2020		31,299
Balance at period start at Dec. 31, 2020	709,038	$ 313	382,628	457,417	(63,681)	(67,639)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Common stock issued under employee plans	8,215		2,944			5,271
Stock-based compensation	3,387		3,387
Dividends on common stock ($0.20 per share)	(5,813)			(5,813)
Comprehensive income (loss):
Cash flow hedging gain (loss), net					3,926
Pension liability, net of income tax					631
Foreign currency translation adjustments					(3,674)
Net income (loss)				9,860
Comprehensive income (loss)	10,743
Balance at period end (shares) at Mar. 31, 2021		31,299
Balance at period end at Mar. 31, 2021	725,570	$ 313	388,959	461,464	(62,798)	(62,368)
Balance at period start (shares) at Dec. 31, 2020		31,299
Balance at period start at Dec. 31, 2020	709,038	$ 313	382,628	457,417	(63,681)	(67,639)
Comprehensive income (loss):
Cash flow hedging gain (loss), net	8,064
Pension liability, net of income tax	1,893
Foreign currency translation adjustments	(5,813)
Net income (loss)	38,098
Comprehensive income (loss)	42,242
Balance at period end (shares) at Sep. 30, 2021		31,299
Balance at period end at Sep. 30, 2021	755,683	$ 313	394,810	478,035	(59,537)	(57,938)
Balance at period start (shares) at Mar. 31, 2021		31,299
Balance at period start at Mar. 31, 2021	725,570	$ 313	388,959	461,464	(62,798)	(62,368)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Common stock issued under employee plans	2,726		414			2,312
Stock-based compensation	4,290		4,290
Dividends on common stock ($0.20 per share)	(5,830)			(5,830)
Comprehensive income (loss):
Cash flow hedging gain (loss), net					1,221
Pension liability, net of income tax					631
Foreign currency translation adjustments					2,601
Net income (loss)				13,290
Comprehensive income (loss)	17,743
Balance at period end (shares) at Jun. 30, 2021		31,299
Balance at period end at Jun. 30, 2021	744,499	$ 313	393,663	468,924	(58,345)	(60,056)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Common stock issued under employee plans	(1,062)		(3,180)			2,118
Stock-based compensation	4,327		4,327
Dividends on common stock ($0.20 per share)	(5,837)			(5,837)
Comprehensive income (loss):
Cash flow hedging gain (loss), net	2,917				2,917
Pension liability, net of income tax	631				631
Foreign currency translation adjustments	(4,740)				(4,740)
Net income (loss)	14,948			14,948
Comprehensive income (loss)	13,756
Balance at period end (shares) at Sep. 30, 2021		31,299
Balance at period end at Sep. 30, 2021	$ 755,683	$ 313	$ 394,810	$ 478,035	$ (59,537)	$ (57,938)

Consolidated Condensed Statem_3

Consolidated Condensed Statements of Shareholders' Equity (Unaudited) (Parenthetical) - $ / shares	3 Months Ended
	Sep. 30, 2021	Jun. 30, 2021	Mar. 31, 2021	Sep. 30, 2020	Jun. 30, 2020	Mar. 31, 2020
Dividends per share of common stock (in dollars per share)	$ 0.20	$ 0.20	$ 0.20	$ 0.20	$ 0.20	$ 0.20

Consolidated Condensed Statem_4

Consolidated Condensed Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020
Cash flows from operating activities:
Net income (loss)	$ 38,098	$ (14,623)
Adjustments to reconcile net income (loss) to net cash provided by operating activities:
Depreciation	12,519	13,617
Amortization of debt discount	7,611	7,239
Amortization of deferred debt issuance costs	2,946	2,697
Amortization	40,747	40,973
Stock-based compensation	12,003	10,119
Deferred income taxes	(1,311)	(786)
Loss on early extinguishment of debt	899	0
Increase (decrease) in cash flows from changes in assets and liabilities:
Accounts receivable	9,890	21,574
Inventories	(34,679)	(19,396)
Accounts payable	(6,223)	1,477
Accrued compensation and benefits	5,030	(8,864)
Other assets	(15,915)	(6,013)
Other liabilities	6,370	(3,628)
Net cash provided by operating activities	77,985	44,386
Cash flows from investing activities:
Proceeds from sale of a facility	0	3,227
Purchases of property, plant and equipment	(11,678)	(9,864)
Payments related to business and asset acquisitions, net of cash acquired	0	(3,852)
Net cash used in investing activities	(11,678)	(10,489)
Cash flows from financing activities:
Payments on term loan	(63,673)	(9,938)
Proceeds from term loan	52,411	0
Payments on revolving line of credit	(272,753)	(142,000)
Proceeds from revolving line of credit	236,753	152,000
Payments for Contingent Consideration	(3,536)	(2,071)
Payments related to debt issuance costs	(2,000)	(2,057)
Dividends paid on common stock	(17,418)	(17,099)
Other, net	9,457	(3,730)
Net cash used in financing activities	(60,759)	(24,895)
Effect of exchange rate changes on cash and cash equivalents	(1,393)	740
Net increase in cash and cash equivalents	4,155	9,742
Cash and cash equivalents at beginning of period	27,356	25,856
Cash and cash equivalents at end of period	31,511	35,598
Non-cash investing and financing activities:
Dividends payable	$ 5,837	$ 5,720

Operations

Operations	9 Months Ended
	Sep. 30, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Operations	OperationsCONMED Corporation (“CONMED”, the “Company”, “we” or “us”) is a medical technology company that provides surgical devices and equipment for minimally invasive procedures.  The Company’s products are used by surgeons and other healthcare professionals in a variety of specialties including orthopedics, general surgery, gynecology, thoracic surgery and gastroenterology.

Interim Financial Information

Interim Financial Information	9 Months Ended
	Sep. 30, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Interim Financial Information	Interim Financial Information The accompanying unaudited consolidated condensed financial statements have been prepared in accordance with generally accepted accounting principles for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by generally accepted accounting principles for annual financial statements. The information herein reflects all normal recurring material adjustments, which are, in the opinion of management, necessary to fairly present the results for the periods presented. The consolidated condensed financial statements herein consist of all wholly-owned domestic and foreign subsidiaries with all significant intercompany transactions eliminated. Results for the period ended September 30, 2021 are not necessarily indicative of the results that may be expected for the year ending December 31, 2021. The consolidated condensed financial statements and notes thereto should be read in conjunction with the consolidated financial statements and notes for the year ended December 31, 2020 included in our Annual Report on Form 10-K. Use of Estimates Preparation of the consolidated condensed financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated condensed financial statements and the reported amounts of revenue and expenses during the reporting period. Due to the COVID-19 pandemic, there has been uncertainty and disruption in the global economy and financial markets. We are not aware of any specific event or circumstance that would require an update to our estimates or judgments or a revision of the carrying value of our assets or liabilities as of October 28, 2021, the date of issuance of this Quarterly Report on Form 10-Q. These estimates may change, as new events occur and additional information is obtained. Actual results could differ materially from these estimates under different assumptions or conditions.

Revenues

Revenues	9 Months Ended
	Sep. 30, 2021
Revenue from Contract with Customer [Abstract]
Revenues	Revenues The following tables present revenue disaggregated by primary geographic market where the products are sold, by product line and timing of revenue recognition: Three Months Ended Three Months Ended September 30, 2021 September 30, 2020 Orthopedic Surgery General Surgery Total Orthopedic Surgery General Surgery Total Primary Geographic Markets United States $ 37,957 $ 98,444 $ 136,401 $ 38,913 $ 95,292 $ 134,205 Europe, Middle East & Africa 24,155 19,905 44,060 23,104 17,584 40,688 Asia Pacific 27,517 16,113 43,630 26,403 15,405 41,808 Americas (excluding the United States) 16,122 8,614 24,736 13,767 7,367 21,134 Total sales from contracts with customers $ 105,751 $ 143,076 $ 248,827 $ 102,187 $ 135,648 $ 237,835 Timing of Revenue Recognition Goods transferred at a point in time $ 96,389 $ 141,798 $ 238,187 $ 93,000 $ 134,745 $ 227,745 Services transferred over time 9,362 1,278 10,640 9,187 903 10,090 Total sales from contracts with customers $ 105,751 $ 143,076 $ 248,827 $ 102,187 $ 135,648 $ 237,835 Nine Months Ended Nine Months Ended September 30, 2021 September 30, 2020 Orthopedic Surgery General Surgery Total Orthopedic Surgery General Surgery Total Primary Geographic Markets United States $ 115,864 $ 288,069 $ 403,933 $ 97,339 $ 243,137 $ 340,476 Europe, Middle East & Africa 77,327 58,594 135,921 62,726 50,345 113,071 Asia Pacific 80,403 44,911 125,314 66,737 34,211 100,948 Americas (excluding the United States) 47,215 24,282 71,497 35,152 19,984 55,136 Total sales from contracts with customers $ 320,809 $ 415,856 $ 736,665 $ 261,954 $ 347,677 $ 609,631 Timing of Revenue Recognition Goods transferred at a point in time $ 291,728 $ 412,298 $ 704,026 $ 237,224 $ 345,068 $ 582,292 Services transferred over time 29,081 3,558 32,639 24,730 2,609 27,339 Total sales from contracts with customers $ 320,809 $ 415,856 $ 736,665 $ 261,954 $ 347,677 $ 609,631 Contract liability balances related to the sale of extended warranties to customers are as follows: September 30, 2021 December 31, 2020 Contract liability $ 15,833 $ 13,666 Revenue recognized during the nine months ended September 30, 2021 and September 30, 2020 from amounts included in contract liabilities at the beginning of the period were $8.4 million and $7.6 million, respectively. There were no material contract assets as of September 30, 2021 and December 31, 2020.

Comprehensive Income (Loss)

Comprehensive Income (Loss)	9 Months Ended
	Sep. 30, 2021
Equity [Abstract]
Comprehensive Income (Loss)	Comprehensive Income (Loss) Comprehensive income (loss) consists of the following: Three Months Ended September 30, Nine Months Ended September 30, 2021 2020 2021 2020 Net income (loss) $ 14,948 $ 6,850 $ 38,098 $ (14,623) Other comprehensive income (loss): Cash flow hedging gain (loss), net of income tax (income tax expense (benefit) of $929 and $(964) for the three months ended September 30, 2021 and 2020, respectively, and $2,568 and $(972) for the nine months ended September 30, 2021 and 2020, respectively) 2,917 (3,026) 8,064 (3,050) Pension liability, net of income tax (income tax expense of $201 and $170 for the three months ended September 30, 2021 and 2020, respectively, and $603 and $510 for the nine months ended September 30, 2021 and 2020, respectively) 631 535 1,893 1,605 Foreign currency translation adjustment (4,740) 4,617 (5,813) (790) Comprehensive income (loss) $ 13,756 $ 8,976 $ 42,242 $ (16,858) Accumulated other comprehensive loss consists of the following: Cash Flow Pension Cumulative Accumulated Balance, December 31, 2020 $ (5,945) $ (36,620) $ (21,116) $ (63,681) Other comprehensive income (loss) before reclassifications, net of tax 5,141 — (5,813) (672) Amounts reclassified from accumulated other comprehensive income (loss) before tax a 3,854 2,496 — 6,350 Income tax (931) (603) — (1,534) Net current-period other comprehensive income (loss) 8,064 1,893 (5,813) 4,144 Balance, September 30, 2021 $ 2,119 $ (34,727) $ (26,929) $ (59,537) Cash Flow Pension Cumulative Accumulated Balance, December 31, 2019 $ 493 $ (31,691) $ (28,079) $ (59,277) Other comprehensive income (loss) before reclassifications, net of tax (1,916) — (790) (2,706) Amounts reclassified from accumulated other comprehensive income (loss) before tax a (1,496) 2,115 — 619 Income tax 362 (510) — (148) Net current-period other comprehensive income (loss) (3,050) 1,605 (790) (2,235) Balance, September 30, 2020 $ (2,557) $ (30,086) $ (28,869) $ (61,512) (a) The cash flow hedging gain (loss) and pension liability accumulated other comprehensive income (loss) components are included in sales or cost of sales and as a component of net periodic pension cost, respectively. Refer to Note 5 and Note 11, respectively, for further details.

Fair Value of Financial Instrum

Fair Value of Financial Instruments	9 Months Ended
	Sep. 30, 2021
Fair Value Disclosures [Abstract]
Fair Value of Financial Instruments	Fair Value of Financial Instruments We enter into derivative instruments for risk management purposes only. We operate internationally and, in the normal course of business, are exposed to fluctuations in interest rates, foreign exchange rates and commodity prices. These fluctuations can increase the costs of financing, investing and operating the business. We use forward contracts, a type of derivative instrument, to manage certain foreign currency exposures. By nature, all financial instruments involve market and credit risks. We enter into forward contracts with major investment grade financial institutions and have policies to monitor the credit risk of those counterparties. While there can be no assurance, we do not anticipate any material non-performance by any of these counterparties. Foreign Currency Forward Contracts. We hedge forecasted intercompany sales denominated in foreign currencies through the use of forward contracts. We account for these forward contracts as cash flow hedges. To the extent these forward contracts meet hedge accounting criteria, changes in their fair value are not included in current earnings but are included in accumulated other comprehensive loss. These changes in fair value will be recognized into earnings as a component of sales or cost of sales when the forecasted transaction occurs. We also enter into forward contracts to exchange foreign currencies for United States dollars in order to hedge our currency transaction exposures on intercompany receivables designated in foreign currencies. These forward contracts settle each month at month-end, at which time we enter into new forward contracts. We have not designated these forward contracts as hedges and have not applied hedge accounting to them. The following table presents the notional contract amounts for forward contracts outstanding: As of FASB ASC Topic 815 Designation September 30, 2021 December 31, 2020 Forward exchange contracts Cash flow hedge $ 178,908 $ 154,504 Forward exchange contracts Non-designated 37,254 42,380 The remaining time to maturity as of September 30, 2021 is within two years for hedge designated foreign exchange contracts and approximately one month for non-hedge designated forward exchange contracts. Statement of comprehensive income (loss) presentation Derivatives designated as cash flow hedges Foreign exchange contracts designated as cash flow hedges had the following effects on accumulated other comprehensive income (loss) ("AOCI") and net earnings on our consolidated condensed statements of comprehensive income (loss) and our consolidated condensed balance sheets: Amount of Gain (Loss) Recognized in AOCI Consolidated Condensed Statements of Comprehensive Income (Loss) Amount of Gain (Loss) Reclassified from AOCI Three Months Ended September 30, Total Amount of Line Item Presented Derivative Instrument 2021 2020 Location of amount reclassified 2021 2020 2021 2020 Foreign exchange contracts $ 3,188 $ (3,542) Net Sales $ 248,827 $ 237,835 $ (1,077) $ 663 Cost of Sales 106,521 104,137 419 (215) Pre-tax gain (loss) $ 3,188 $ (3,542) $ (658) $ 448 Tax expense (benefit) 770 (856) (159) 108 Net gain (loss) $ 2,418 $ (2,686) $ (499) $ 340 Amount of Gain (Loss) Recognized in AOCI Consolidated Condensed Statements of Comprehensive Income (Loss) Amount of Gain (Loss) Reclassified from AOCI Nine Months Ended September 30, Total Amount of Line Item Presented Derivative Instrument 2021 2020 Location of amount reclassified 2021 2020 2021 2020 Foreign exchange contracts $ 6,778 $ (2,526) Net Sales $ 736,665 $ 609,631 $ (4,948) $ 2,206 Cost of Sales 324,485 284,845 1,094 (710) Pre-tax gain (loss) $ 6,778 $ (2,526) $ (3,854) $ 1,496 Tax expense (benefit) 1,637 (610) (931) 362 Net gain (loss) $ 5,141 $ (1,916) $ (2,923) $ 1,134 At September 30, 2021, $1.5 million of net unrealized gains on forward contracts accounted for as cash flow hedges, and included in accumulated other comprehensive loss, are expected to be recognized in earnings in the next twelve months. Derivatives not designated as cash flow hedges Net losses from derivative instruments not accounted for as hedges and gains and losses on our intercompany receivables on our consolidated condensed statements of comprehensive income (loss) were: Three Months Ended September 30, Nine Months Ended September 30, Derivative Instrument Location on Consolidated Condensed Statements of Comprehensive Income (Loss) 2021 2020 2021 2020 Net loss on currency forward contracts Selling and administrative expense $ (48) $ (682) $ (398) $ (1,224) Net gain (loss) on currency transaction exposures Selling and administrative expense $ (441) $ 312 $ (1,320) $ 143 Balance sheet presentation We record these forward foreign exchange contracts at fair value. The following tables summarize the fair value for forward foreign exchange contracts outstanding at September 30, 2021 and December 31, 2020: September 30, 2021 Location on Consolidated Condensed Balance Sheet Asset Fair Value Liabilities Fair Value Net Derivatives designated as hedged instruments: Foreign exchange contracts Prepaid expenses and other current assets $ 3,319 $ (1,311) $ 2,008 Foreign exchange contracts Other long-term assets 932 (145) 787 $ 4,251 $ (1,456) $ 2,795 Derivatives not designated as hedging instruments: Foreign exchange contracts Other current liabilities 21 (160) (139) Total derivatives $ 4,272 $ (1,616) $ 2,656 December 31, 2020 Location on Consolidated Condensed Balance Sheet Asset Fair Value Liabilities Fair Value Net Derivatives designated as hedged instruments: Foreign exchange contracts Other current liabilities $ 1,500 $ (8,826) $ (7,326) Foreign exchange contracts Other long-term liabilities 23 (535) (512) $ 1,523 $ (9,361) $ (7,838) Derivatives not designated as hedging instruments: Foreign exchange contracts Other current liabilities 25 (150) (125) Total derivatives $ 1,548 $ (9,511) $ (7,963) Our forward foreign exchange contracts are subject to a master netting agreement and qualify for netting in the consolidated condensed balance sheets. Fair Value Disclosure. FASB guidance defines fair value and establishes a framework for measuring fair value and related disclosure requirements. This guidance applies when fair value measurements are required or permitted. The guidance indicates, among other things, that a fair value measurement assumes that the transaction to sell an asset or transfer a liability occurs in the principal market for the asset or liability or, in the absence of a principal market, the most advantageous market for the asset or liability. Fair value is defined based upon an exit price model. Valuation Hierarchy. A valuation hierarchy was established for disclosure of the inputs to the valuations used to measure fair value. This hierarchy prioritizes the inputs into three broad levels as follows. Level 1 inputs are quoted prices (unadjusted) in active markets for identical assets or liabilities. Level 2 inputs are quoted prices for similar assets and liabilities in active markets, quoted prices for identical or similar assets in markets that are not active, inputs other than quoted prices that are observable for the asset or liability, including interest rates, yield curves and credit risks, or inputs that are derived principally from or corroborated by observable market data through correlation. Level 3 inputs are unobservable inputs based on our own assumptions used to measure assets and liabilities at fair value. A financial asset or liability’s classification within the hierarchy is determined based on the lowest level input that is significant to the fair value measurement. There have been no significant changes in the assumptions. Valuation Techniques. Assets and liabilities carried at fair value and measured on a recurring basis as of September 30, 2021 consist of forward foreign exchange contracts. The Company values its forward foreign exchange contracts using quoted prices for similar assets. The most significant assumption is quoted currency rates. The value of the forward foreign exchange contract assets and liabilities were valued using Level 2 inputs and are listed in the table above.

Inventories

Inventories	9 Months Ended
	Sep. 30, 2021
Inventory Disclosure [Abstract]
Inventories	Inventories Inventories consist of the following: September 30, December 31, Raw materials $ 76,637 $ 71,807 Work-in-process 17,658 15,864 Finished goods 134,277 107,197 Total $ 228,572 $ 194,868

Earnings (Loss) Per Share

Earnings (Loss) Per Share	9 Months Ended
	Sep. 30, 2021
Earnings Per Share [Abstract]
Earnings (Loss) Per Share	Earnings (Loss) Per ShareBasic earnings (loss) per share (“basic EPS”) is computed by dividing net income (loss) by the weighted average number of common shares outstanding for the reporting period. Diluted earnings (loss) per share (“diluted EPS”) gives effect to all dilutive potential shares outstanding resulting from employee stock options, restricted stock units, performance share units and stock appreciation rights ("SARs") as well as the Notes and related hedge transactions during the period. The following table sets forth the computation of basic and diluted earnings (loss) per share for the three and nine months ended September 30, 2021 and 2020: Three Months Ended September 30, Nine Months Ended September 30, 2021 2020 2021 2020 Net income (loss) $ 14,948 $ 6,850 $ 38,098 $ (14,623) Basic – weighted average shares outstanding 29,179 28,583 29,097 28,529 Effect of dilutive potential securities 2,964 843 2,923 — Diluted – weighted average shares outstanding 32,143 29,426 32,020 28,529 Net income (loss) (per share) Basic $ 0.51 $ 0.24 $ 1.31 $ (0.51) Diluted 0.47 0.23 1.19 (0.51) The shares used in the calculation of diluted EPS exclude options and SARs to purchase shares where the exercise price was greater than the average market price of common shares for the period and the effect of the inclusion would be anti-dilutive. Such shares aggregated approximately 0.7 million and 0.5 million for the three and nine months ended September 30, 2021, respectively, and 1.6 million for the three months ended September 30, 2020. As the Company was in a net loss position for the nine months ended September 30, 2020, there were no anti-dilutive shares. Our 2.625% convertible notes due in 2024 (the “Notes”) are convertible under certain circumstances, as defined in the indenture, into a combination of cash and CONMED common stock. The following is intended to describe the impact of the Notes and related hedge transactions on the calculation of diluted EPS. Additional shares to be issued pursuant to the terms of the Notes and related hedge transactions, if any, would occur at maturity. The calculation of diluted EPS includes potential diluted shares upon conversion of the Notes when the average market price per share of our common stock for the period is greater than the conversion price of the Notes of $88.80. We intend to settle in cash the principal outstanding and use the treasury stock method when calculating their potential dilutive effect, if any. During the three and nine months ended September 30, 2021, our average share price exceeded the conversion price of the Notes and we included in our diluted share count 1.2 million shares, for both periods, assumed to be issued if the Notes were converted. During the three and nine months ended September 30, 2020, our average share price had not exceeded the conversion price of the Notes; therefore, under the net share settlement method, there were no potential shares issuable under the Notes to be used in the calculation of diluted EPS. We previously entered into convertible notes hedge transactions to increase the effective conversion price of the Notes to $114.92. However, our convertible notes hedges are not included when calculating potential dilutive shares since their effect is always anti-dilutive. Concurrently with entering into the hedge transactions, we also previously entered into warrant transactions under which we agreed to sell shares of our common stock at $114.92. The calculation of diluted EPS also includes

Goodwill and Other Intangible A

Goodwill and Other Intangible Assets	9 Months Ended
	Sep. 30, 2021
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill and Other Intangible Assets	Goodwill and Other Intangible Assets The changes in the net carrying amount of goodwill for the nine months ended September 30, 2021 are as follows: Balance as of December 31, 2020 $ 618,440 Foreign currency translation (789) Balance as of September 30, 2021 $ 617,651 Assets and liabilities of acquired businesses are recorded at their estimated fair values as of the date of acquisition. Goodwill represents costs in excess of fair values assigned to the underlying net assets of acquired businesses. Other intangible assets consist of the following: September 30, 2021 December 31, 2020 Weighted Average Amortization Period (Years) Gross Accumulated Gross Accumulated Intangible assets with definite lives: 22 Customer and distributor relationships 24 $ 342,501 $ (148,330) $ 342,639 $ (134,555) Sales representation, marketing and promotional rights 25 149,376 (58,500) 149,376 (54,000) Developed technology 16 106,604 (24,801) 106,604 (19,705) Patents and other intangible assets 16 75,836 (50,369) 73,516 (48,882) Intangible assets with indefinite lives: Trademarks and tradenames 86,544 — 86,544 — $ 760,861 $ (282,000) $ 758,679 $ (257,142) Customer and distributor relationships, trademarks and tradenames, developed technology and patents and other intangible assets primarily represent allocations of purchase price to identifiable intangible assets of acquired businesses. Sales representation, marketing and promotional rights represent intangible assets created under our agreement with Musculoskeletal Transplant Foundation (“MTF”). Amortization expense related to intangible assets which are subject to amortization totaled $8.3 million and $8.6 million in the three months ended September 30, 2021 and 2020, respectively, and $24.9 million and $25.6 million in the nine months ended September 30, 2021 and 2020, respectively, and is included as a reduction of revenue (for amortization related to our sales representation, marketing and promotional rights) and in selling and administrative expense (for all other intangible assets) in the consolidated condensed statements of comprehensive income (loss). Included in developed technology is $3.5 million of earn-out consideration that was paid during the third quarter of 2021 and an additional accrual of $2.4 million of earn-out consideration that is considered probable as of September 30, 2021 associated with a prior asset acquisition. This is recorded in other current liabilities at September 30, 2021. The estimated intangible asset amortization expense remaining for the year ending December 31, 2021 and for each of the five succeeding years is as follows: Amortization included in expense Amortization recorded as a reduction of revenue Total Remaining, 2021 $ 7,187 $ 1,500 $ 8,687 2022 26,554 6,000 32,554 2023 25,679 6,000 31,679 2024 24,929 6,000 30,929 2025 25,145 6,000 31,145 2026 24,652 6,000 30,652

Long Term Debt

Long Term Debt	9 Months Ended
	Sep. 30, 2021
Debt Disclosure [Abstract]
Long-term Debt	Long-Term Debt Long-term debt consists of the following: September 30, 2021 December 31, 2020 Revolving line of credit $ 171,000 $ 207,000 Term loan, net of deferred debt issuance costs of $1,448 and $1,668 in 2021 and 2020, respectively 229,102 240,145 2.625% convertible notes, net of deferred debt issuance costs of $4,144 and $5,475 in 2021 and 2020, respectively, and unamortized discount of $26,009 and $33,620 in 2021 and 2020, respectively 314,846 305,904 Financing leases 638 587 Total debt 715,586 753,636 Less: Current portion 12,251 18,415 Total long-term debt $ 703,335 $ 735,221 On July 16, 2021, we entered into a seventh amended and restated senior credit agreement consisting of: (a) a $233.5 million term loan facility and (b) a $585.0 million revolving credit facility. The revolving credit facility will terminate and the loans outstanding under the term loan facility will expire on July 16, 2026. The term loan is payable in quarterly installments increasing over the term of the facility. Proceeds from the term loan facility and borrowings under the revolving credit facility were used to repay the then existing senior credit agreement. Interest rates are at LIBOR (subject to 0.125% floor) plus an interest rate margin of 1.50% (1.625% at September 30, 2021). For borrowings where we elect to use the alternate base rate, the initial base rate is the greatest of (i) the Prime Rate, (ii) the Federal Funds Rate plus 0.50% or (iii) the one-month Adjusted LIBOR plus 1.00%, plus, in each case, an interest rate margin. There were $230.5 million in borrowings outstanding on the term loan facility as of September 30, 2021. There were $171.0 million in borrowings outstanding under the revolving credit facility as of September 30, 2021. Our available borrowings on the revolving credit facility at September 30, 2021 were $411.5 million with approximately $2.5 million of the facility set aside for outstanding letters of credit. The seventh amended and restated senior credit agreement is collateralized by substantially all of our personal property and assets. The seventh amended and restated senior credit agreement contains covenants and restrictions which, among other things, require the maintenance of certain financial ratios and restrict dividend payments and the incurrence of certain indebtedness and other activities, including acquisitions and dispositions. We were in full compliance with these covenants and restrictions as of September 30, 2021. We are also required, under certain circumstances, to make mandatory prepayments from net cash proceeds from any issuance of equity and asset sales. On January 29, 2019, we issued $345.0 million in 2.625% convertible notes due in 2024 (the "Notes"). Interest is payable semi-annually in arrears on February 1 and August 1 of each year, commencing August 1, 2019. The Notes will mature on February 1, 2024, unless earlier repurchased or converted. The Notes represent subordinated unsecured obligations and are convertible under certain circumstances, as defined in the indenture, into a combination of cash and CONMED common stock. The Notes may be converted at an initial conversion rate of 11.2608 shares of our common stock per $1,000 principal amount of Notes (equivalent to an initial conversion price of approximately $88.80 per share of common stock). Holders of the Notes may convert the Notes at their option at any time on or after November 1, 2023 through the second scheduled trading day preceding the maturity date. Holders of the Notes will also have the right to convert the Notes prior to November 1, 2023, but only upon the occurrence of specified events. The conversion rate is subject to anti-dilution adjustments if certain events occur. A portion of the net proceeds from the offering of the Notes were used as part of the financing for the Buffalo Filter acquisition and $21.0 million were used to pay the cost of certain convertible notes hedge transactions as further described below. Our effective borrowing rate for nonconvertible debt at the time of issuance of the Notes was estimated to be 6.14%, which resulted in $51.6 million of the $345.0 million aggregate principal amount of Notes issued, or $39.1 million after taxes, being attributable to equity. For the three months ended September 30, 2021 and 2020, we have recorded interest expense related to the amortization of debt discount on the Notes of $2.6 million and $2.4 million, respectively, and for the nine months ended September 30, 2021 and 2020, we have recorded interest expense related to the amortization of debt discount on the Notes of $7.6 million and $7.2 million, respectively, at the effective interest rate of 6.14%. The debt discount on the Notes is being amortized through February 2024. For both the three months ended September 30, 2021 and 2020, we have recorded interest expense on the Notes of $2.3 million and for both the nine months ended September 30, 2021 and 2020, we have recorded interest expense on the Notes of $6.8 million at the contractual coupon rate of 2.625%. In connection with the offering of the Notes, we entered into convertible note hedge transactions with a number of financial institutions (each, an “option counterparty”). The convertible note hedge transactions cover, subject to anti-dilution adjustments substantially similar to those applicable to the Notes, the number of shares of our common stock underlying the Notes. Concurrently with entering into the convertible note hedge transactions, we also entered into separate warrant transactions with each option counterparty whereby we sold to such option counterparty warrants to purchase, subject to customary anti-dilution adjustments, the same number of shares of our common stock. The convertible note hedge transactions are expected generally to reduce the potential dilution upon conversion of the Notes and/or offset any cash payments we are required to make in excess of the principal amount of converted Notes, as the case may be, in the event that the market price per share of our common stock, as measured under the terms of the convertible note hedge transactions, is greater than the strike price of the convertible note hedge transactions, which initially corresponds to the conversion price of the Notes and is subject to anti-dilution adjustments substantially similar to those applicable to the conversion rate of the Notes. If, however, the market price per share of our common stock, as measured under the terms of the warrant transactions, exceeds the strike price ($114.92) of the warrants, there would nevertheless be dilution to the extent that such market price exceeds the strike price of the warrants as noted in Note 7, unless we elect to settle the warrants in cash. The scheduled maturities of long-term debt outstanding at September 30, 2021 are as follows: Remaining 2021 $ 2,981 2022 11,925 2023 14,906 2024 365,869 2025 23,850 2026 327,018 The above amounts exclude debt discount, deferred debt issuance costs and financing leases.

Guarantees

Guarantees	9 Months Ended
	Sep. 30, 2021
Guarantees [Abstract]
Guarantees	GuaranteesWe provide warranties on certain of our products at the time of sale and sell extended warranties. The standard warranty period for our capital equipment is generally one year and our extended warranties typically vary from one to three years. Liability under warranty policies is based upon a review of historical claim experience. Adjustments are made to accruals as claim data and historical experience warrant. Changes in the liability for standard warranties for the nine months ended September 30, are as follows: 2021 2020 Balance as of January 1, $ 1,826 $ 2,186 Provision for warranties 1,235 616 Claims made (683) (932) Balance as of September 30, $ 2,378 $ 1,870 Costs associated with extended warranty repairs are recorded as incurred and amounted to $5.2 million and $4.4 million for the nine months ended September 30, 2021 and 2020, respectively.

Pension Plan

Pension Plan	9 Months Ended
	Sep. 30, 2021
Retirement Benefits [Abstract]
Pension Plan	Pension Plan Net periodic pension cost consists of the following: Three Months Ended September 30, Nine Months Ended September 30, 2021 2020 2021 2020 Service cost $ 248 $ 179 $ 744 $ 537 Interest cost on projected benefit obligation 451 639 1,353 1,917 Expected return on plan assets (1,289) (1,255) (3,867) (3,765) Net amortization and deferral 832 705 2,496 2,115 Net periodic pension cost $ 242 $ 268 $ 726 $ 804

Acquisition and Other Expense

Acquisition and Other Expense	9 Months Ended
	Sep. 30, 2021
Acquisition and Other Expense [Abstract]
Acquisition and Other Expense	Acquisition and Other Expense Acquisition and other expense consist of the following, which are included in cost of sales, selling and administrative expense or other expense depending on the nature of the charge: Three Months Ended September 30, Nine Months Ended September 30, 2021 2020 2021 2020 Plant underutilization costs $ — $ — $ — $ 6,586 Product rationalization costs - inventory — — — 2,169 Restructuring costs — — — 1,087 Manufacturing consolidation costs — 606 — 3,993 Acquisition and integration costs — 796 — 2,253 Acquisition and other expense included in cost of sales $ — $ 1,402 $ — $ 16,088 Restructuring and related costs $ — $ 1,009 $ 414 $ 3,133 Product rationalization costs - field inventory — — — 2,095 Acquisition and integration costs — — — 1,192 Acquisition and other expense included in selling and administrative expense $ — $ 1,009 $ 414 $ 6,420 Debt refinancing costs included in other expense $ 1,127 $ — $ 1,127 $ — During the nine months ended September 30, 2020, we recorded a $6.6 million charge to cost of sales related to plant underutilization due to abnormally low production as a result of decreased sales caused by the COVID-19 pandemic. During the nine months ended September 30, 2020, we performed an analysis of our product lines and determined certain catalog numbers, principally related to capital equipment, would be discontinued and consolidated into existing product offerings. We consequently recorded a $2.2 million charge to cost of sales to write-off inventory of the discontinued products. In addition, we incurred $2.1 million in costs related to the write-off of field inventory used for customer demonstration and evaluation of the discontinued products which we charged to selling and administrative expense. During the nine months ended September 30, 2020, we incurred $1.1 million in restructuring costs related to a voluntary separation arrangement with employees as a result of the COVID-19 pandemic that were charged to cost of sales based on the job function of the affected employees. During the three and nine months ended September 30, 2020, we incurred $0.6 million and $4.0 million, respectively, in costs related to the consolidation of certain manufacturing operations which were charged to cost of sales. These costs related to winding down operations at certain locations and moving production lines to other facilities. During the three and nine months ended September 30, 2020, we incurred costs for inventory step-up adjustments and other costs of $0.8 million and $2.3 million, respectively, related to a previous acquisition, which were charged to cost of sales. During the three and nine months ended September 30, 2020 we recorded charges of $1.0 million and $2.3 million, respectively, primarily related to the restructuring of our Orthopedic sales force that was charged to selling and administrative expenses based on the nature of the costs and function of the affected employees. During the nine months ended September 30, 2021, we recorded a charge of $0.4 million related to the restructuring of our sales force which consisted primarily of termination payments to Orthopedic distributors made in exchange for ongoing assistance to transition to employee-based sales representatives and severance that was charged to selling and administrative expenses. During the nine months ended September 30, 2020, we incurred $0.8 million in restructuring charges principally related to a voluntary separation arrangement with employees as a result of the COVID-19 pandemic which were charged to selling and administrative expense based on the nature of the costs and function of the affected employees. During the nine months ended September 30, 2020, we incurred $1.2 million in severance and integration costs mainly related to the Buffalo Filter acquisition which were included in selling and administrative expense. During the three and nine months ended September 30, 2021, we recorded $1.1 million related to a loss on early extinguishment and third party fees associated with the seventh amended and restated senior credit agreement as further described in Note 9. These costs were included in other expense.

Business Segment

Business Segment	9 Months Ended
	Sep. 30, 2021
Segment Reporting [Abstract]
Business Segment	Business Segment We are accounting and reporting for our business as a single operating segment entity engaged in the development, manufacturing and sale on a global basis of surgical devices and related equipment. Our chief operating decision maker (the CEO) evaluates the various global product portfolios on a net sales basis and evaluates profitability, investment, cash flow metrics and allocates resources on a consolidated worldwide basis due to shared infrastructure and resources. Our product lines consist of orthopedic surgery and general surgery. Orthopedic surgery consists of sports medicine instrumentation and small bone, large bone and specialty powered surgical instruments as well as imaging systems for use in minimally invasive surgery procedures and fees related to the sales representation, promotion and marketing of sports medicine allograft tissue. General surgery consists of a complete line of endo-mechanical instrumentation for minimally invasive laparoscopic and gastrointestinal procedures, smoke evacuation devices, a line of cardiac monitoring products as well as electrosurgical generators and related instruments. These product lines' net sales are as follows: Three Months Ended September 30, Nine Months Ended September 30, 2021 2020 2021 2020 Orthopedic surgery $ 105,751 $ 102,187 $ 320,809 $ 261,954 General surgery 143,076 135,648 415,856 347,677 Consolidated net sales $ 248,827 $ 237,835 $ 736,665 $ 609,631

Legal Proceedings

Legal Proceedings	9 Months Ended
	Sep. 30, 2021
Commitments and Contingencies Disclosure [Abstract]
Legal Proceedings	Legal Proceedings From time to time, the Company may receive an information request, subpoena or warrant from a government agency such as the Securities and Exchange Commission, Department of Justice, Equal Employment Opportunity Commission, the Occupational Safety and Health Administration, the United States Food and Drug Administration, the Department of Labor, the Treasury Department or other federal and state agencies or foreign governments or government agencies. These information requests, subpoenas or warrants may or may not be routine inquiries, or may begin as routine inquiries and over time develop into enforcement actions of various types. Likewise, if we receive reports of alleged misconduct from employees and third parties, we investigate as appropriate. Manufacturers of medical devices have been the subject of various enforcement actions relating to interactions with health care providers domestically or internationally whereby companies are claimed to have provided health care providers with inappropriate incentives to purchase their products. Similarly, the Foreign Corrupt Practices Act ("FCPA") imposes obligations on manufacturers with respect to interactions with health care providers who may be considered government officials based on their affiliation with public hospitals. The FCPA also requires publicly listed manufacturers to maintain accurate books and records, and maintain internal accounting controls sufficient to provide assurance that transactions are accurately recorded, lawful and in accordance with management's authorization. The FCPA poses unique challenges both because manufacturers operate in foreign cultures in which conduct illegal under the FCPA may not be illegal in local jurisdictions, and because, in some cases, a United States manufacturer may face risks under the FCPA based on the conduct of third parties over whom the manufacturer may not have complete control. While CONMED has not experienced any material enforcement action to date, there can be no assurance that the Company will not be subject to a material enforcement action in the future, or that the Company will not incur costs including, in the form of fees for lawyers and other consultants, that are material to the Company’s results of operations in the course of responding to a future inquiry or investigation. Manufacturers of medical products may face exposure to significant product liability claims, as well as patent infringement and other claims incurred in the ordinary course of business. To date, we have not experienced any claims that have been material to our financial statements or financial condition, but any such claims arising in the future could have a material adverse effect on our business, results of operations or cash flows. We currently maintain commercial product liability insurance of $35 million per incident and $35 million in the aggregate annually, which we believe is adequate. This coverage is on a claims-made basis. There can be no assurance that claims will not exceed insurance coverage, that the carriers will be solvent or that such insurance will be available to us in the future at a reasonable cost. Our operations are subject, and in the past have been subject, to a number of environmental laws and regulations governing, among other things, air emissions; wastewater discharges; the use, handling and disposal of hazardous substances and wastes; soil and groundwater remediation and employee health and safety. Likewise, the operations of our suppliers and sterilizers are subject to similar environmental laws and regulations. In some jurisdictions, environmental requirements may be expected to become more stringent in the future. In the United States, certain environmental laws can impose liability for the entire cost of site restoration upon each of the parties that may have contributed to conditions at the site regardless of fault or the lawfulness of the party’s activities. While we do not believe that the present costs of environmental compliance and remediation are material, there can be no assurance that future compliance or remedial obligations would not have a material adverse effect on our financial condition, results of operations or cash flows. In 2014, the Company acquired EndoDynamix, Inc. The agreement governing the terms of the acquisition provides that, if various conditions are met, certain contingent payments relating to the first commercial sale of the products (the milestone payment), as well as royalties based on sales (the revenue based payments), are due to the seller. In 2016, we notified the seller that there was a need to redesign the product, and that, as a consequence, the first commercial sale had been delayed. Consequently, the payment of contingent milestone and revenue-based payments were delayed. On January 18, 2017, the seller provided notice (the "Notice") seeking $12.7 million under a liquidated damages clause, which essentially represents the seller's view as to the sum of the projected contingent milestone and revenue-based payments on an accelerated basis. CONMED responded to the Notice denying that there was any basis for acceleration of the payments due under the acquisition agreement. On February 22, 2017, the representative of the former shareholders of EndoDynamix filed a complaint in Delaware Chancery Court claiming breach of contract with respect to the duty to commercialize the product and seeking the contingent payments on an accelerated basis. We believe that there was a substantive contractual basis to support the Company's decision to redesign the product, such that there was no legitimate basis for seeking the liquidated damages. In the third quarter of 2018, the Company decided to halt the development of the EndoDynamix clip applier and recorded a charge to write off assets and released a previously accrued contingent consideration liability. In court filings the Plaintiffs claim to seek liquidated damages, as well as additional damages up to $24.8 million. A non-jury trial in the Delaware Chancery Court commenced on March 18, 2021, and testimony concluded on April 7, 2021. The parties have submitted post-trial briefs, and the Court heard oral arguments at a hearing on September 16, 2021. The Court has not yet issued a ruling. The Company has not recorded any expense related to potential damages in connection with this matter because the Company does not believe any potential loss is probable. We expect to defend the claims asserted by the sellers of EndoDynamix, although there can be no assurance that we will prevail in the trial and/or any resulting appeals. CONMED is defending two Georgia State Court actions. The first was filed by various employees, former employees, contract workers and others against CONMED, and against a contract sterilizer. The second action is against CONMED’s landlord and other allegedly related entities. Plaintiffs in the lawsuits allege personal injury and related claims purportedly arising from or relating to exposure to Ethylene Oxide, a chemical used to sterilize certain products. CONMED is defending the claims asserted directly against it and is providing indemnification for certain other defendants based on contractual provisions. CONMED has submitted all of the claims for insurance coverage. One insurer is providing coverage for certain of the claims asserted directly against the Company. CONMED is currently in litigation with one of the other insurers regarding coverage for certain of the indemnification claims. The Company is unable to estimate any range of possible loss at this time, and has not recorded any expense related to potential damages in connection with this matter because the Company does not believe any potential loss is probable. Both actions are in their early stages and discovery has not yet started. CONMED believes it has strong defenses to the claims and will vigorously defend itself and all parties it is indemnifying. As with any litigation, there are risks, including the risk that CONMED may not prevail with respect to the defense of the underlying claims, or with respect to securing adequate insurance coverage for the indemnification claims. We record reserves sufficient to cover probable and estimable losses associated with any such pending claims. We do not expect that the resolution of any pending claims, investigations or reports of alleged misconduct will have a material adverse effect on our financial condition, results of operations or cash flows. There can be no assurance, however, that future claims or investigations, or the costs associated with responding to such claims, investigations or reports of misconduct, especially claims and investigations not covered by insurance, will not have a material adverse effect on our financial condition, results of operations or cash flows.

New Accounting Pronouncements

New Accounting Pronouncements	9 Months Ended
	Sep. 30, 2021
Accounting Standards Update and Change in Accounting Principle [Abstract]
New Accounting Pronouncements	New Accounting Pronouncements Recently Issued Accounting Standards, Not Yet Adopted In March 2020, the FASB issued ASU 2020-04, Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting, which provides optional guidance if certain criteria are met for entities that have contracts, hedging relationships, and other transactions that reference LIBOR or other reference rates expected to be discontinued as a result of reference rate reform. This ASU is effective as of March 12, 2020 through December 31, 2022. The Company has not adopted this ASU as of September 30, 2021, however will continue to monitor the impact of reference rates and will elect to apply this guidance in our consolidated financial statements in the event that we are impacted by reference rate reform. In August 2020, the FASB issued ASU 2020-06, Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity, which simplifies the accounting for convertible instruments by removing certain separation models requiring separate accounting for embedded conversion features which will result in more convertible debt instruments accounted for as a single liability. The ASU eliminates certain settlement conditions that are required for equity classification to qualify for the derivative scope exception. The ASU addresses how convertible instruments are accounted for in the calculation of diluted earnings per share by using the if-converted method. The ASU is effective for fiscal years beginning after December 15, 2021, with early adoption permitted no earlier than fiscal years beginning after December 15, 2020. The Company will adopt this standard on January 1, 2022 using the modified retrospective method. The estimated impacts include the convertible debt instrument being accounted for as a single liability measured at its amortized cost and elimination of the non-cash interest expense as the Company will not separately present the equity embedded conversion feature in such debt. The Company also expects to adopt the if-converted method for earnings per share.

Interim Reporting (Policies)

Interim Reporting (Policies)	9 Months Ended
	Sep. 30, 2021
Quarterly Financial Information Disclosure [Abstract]
Use of Estimates	Use of Estimates Preparation of the consolidated condensed financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated condensed financial statements and the reported amounts of revenue and expenses during the reporting period.

New Accounting Pronouncements (

New Accounting Pronouncements (Policies)	9 Months Ended
	Sep. 30, 2021
Accounting Standards Update and Change in Accounting Principle [Abstract]
New Accounting Pronouncements	New Accounting Pronouncements Recently Issued Accounting Standards, Not Yet Adopted In March 2020, the FASB issued ASU 2020-04, Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting, which provides optional guidance if certain criteria are met for entities that have contracts, hedging relationships, and other transactions that reference LIBOR or other reference rates expected to be discontinued as a result of reference rate reform. This ASU is effective as of March 12, 2020 through December 31, 2022. The Company has not adopted this ASU as of September 30, 2021, however will continue to monitor the impact of reference rates and will elect to apply this guidance in our consolidated financial statements in the event that we are impacted by reference rate reform. In August 2020, the FASB issued ASU 2020-06, Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity, which simplifies the accounting for convertible instruments by removing certain separation models requiring separate accounting for embedded conversion features which will result in more convertible debt instruments accounted for as a single liability. The ASU eliminates certain settlement conditions that are required for equity classification to qualify for the derivative scope exception. The ASU addresses how convertible instruments are accounted for in the calculation of diluted earnings per share by using the if-converted method. The ASU is effective for fiscal years beginning after December 15, 2021, with early adoption permitted no earlier than fiscal years beginning after December 15, 2020. The Company will adopt this standard on January 1, 2022 using the modified retrospective method. The estimated impacts include the convertible debt instrument being accounted for as a single liability measured at its amortized cost and elimination of the non-cash interest expense as the Company will not separately present the equity embedded conversion feature in such debt. The Company also expects to adopt the if-converted method for earnings per share.

Revenues (Tables)

Revenues (Tables)	9 Months Ended
	Sep. 30, 2021
Revenue from Contract with Customer [Abstract]
Disaggregation of Revenue	The following tables present revenue disaggregated by primary geographic market where the products are sold, by product line and timing of revenue recognition: Three Months Ended Three Months Ended September 30, 2021 September 30, 2020 Orthopedic Surgery General Surgery Total Orthopedic Surgery General Surgery Total Primary Geographic Markets United States $ 37,957 $ 98,444 $ 136,401 $ 38,913 $ 95,292 $ 134,205 Europe, Middle East & Africa 24,155 19,905 44,060 23,104 17,584 40,688 Asia Pacific 27,517 16,113 43,630 26,403 15,405 41,808 Americas (excluding the United States) 16,122 8,614 24,736 13,767 7,367 21,134 Total sales from contracts with customers $ 105,751 $ 143,076 $ 248,827 $ 102,187 $ 135,648 $ 237,835 Timing of Revenue Recognition Goods transferred at a point in time $ 96,389 $ 141,798 $ 238,187 $ 93,000 $ 134,745 $ 227,745 Services transferred over time 9,362 1,278 10,640 9,187 903 10,090 Total sales from contracts with customers $ 105,751 $ 143,076 $ 248,827 $ 102,187 $ 135,648 $ 237,835 Nine Months Ended Nine Months Ended September 30, 2021 September 30, 2020 Orthopedic Surgery General Surgery Total Orthopedic Surgery General Surgery Total Primary Geographic Markets United States $ 115,864 $ 288,069 $ 403,933 $ 97,339 $ 243,137 $ 340,476 Europe, Middle East & Africa 77,327 58,594 135,921 62,726 50,345 113,071 Asia Pacific 80,403 44,911 125,314 66,737 34,211 100,948 Americas (excluding the United States) 47,215 24,282 71,497 35,152 19,984 55,136 Total sales from contracts with customers $ 320,809 $ 415,856 $ 736,665 $ 261,954 $ 347,677 $ 609,631 Timing of Revenue Recognition Goods transferred at a point in time $ 291,728 $ 412,298 $ 704,026 $ 237,224 $ 345,068 $ 582,292 Services transferred over time 29,081 3,558 32,639 24,730 2,609 27,339 Total sales from contracts with customers $ 320,809 $ 415,856 $ 736,665 $ 261,954 $ 347,677 $ 609,631
Contract with Customer, Asset and Liability	Contract liability balances related to the sale of extended warranties to customers are as follows: September 30, 2021 December 31, 2020 Contract liability $ 15,833 $ 13,666

Comprehensive Income (Loss) (Ta

Comprehensive Income (Loss) (Tables)	9 Months Ended
	Sep. 30, 2021
Equity [Abstract]
Schedule of Comprehensive Income (Loss)	Comprehensive income (loss) consists of the following: Three Months Ended September 30, Nine Months Ended September 30, 2021 2020 2021 2020 Net income (loss) $ 14,948 $ 6,850 $ 38,098 $ (14,623) Other comprehensive income (loss): Cash flow hedging gain (loss), net of income tax (income tax expense (benefit) of $929 and $(964) for the three months ended September 30, 2021 and 2020, respectively, and $2,568 and $(972) for the nine months ended September 30, 2021 and 2020, respectively) 2,917 (3,026) 8,064 (3,050) Pension liability, net of income tax (income tax expense of $201 and $170 for the three months ended September 30, 2021 and 2020, respectively, and $603 and $510 for the nine months ended September 30, 2021 and 2020, respectively) 631 535 1,893 1,605 Foreign currency translation adjustment (4,740) 4,617 (5,813) (790) Comprehensive income (loss) $ 13,756 $ 8,976 $ 42,242 $ (16,858)
Schedule of Accumulated Other Comprehensive Loss	Accumulated other comprehensive loss consists of the following: Cash Flow Pension Cumulative Accumulated Balance, December 31, 2020 $ (5,945) $ (36,620) $ (21,116) $ (63,681) Other comprehensive income (loss) before reclassifications, net of tax 5,141 — (5,813) (672) Amounts reclassified from accumulated other comprehensive income (loss) before tax a 3,854 2,496 — 6,350 Income tax (931) (603) — (1,534) Net current-period other comprehensive income (loss) 8,064 1,893 (5,813) 4,144 Balance, September 30, 2021 $ 2,119 $ (34,727) $ (26,929) $ (59,537) Cash Flow Pension Cumulative Accumulated Balance, December 31, 2019 $ 493 $ (31,691) $ (28,079) $ (59,277) Other comprehensive income (loss) before reclassifications, net of tax (1,916) — (790) (2,706) Amounts reclassified from accumulated other comprehensive income (loss) before tax a (1,496) 2,115 — 619 Income tax 362 (510) — (148) Net current-period other comprehensive income (loss) (3,050) 1,605 (790) (2,235) Balance, September 30, 2020 $ (2,557) $ (30,086) $ (28,869) $ (61,512) (a) The cash flow hedging gain (loss) and pension liability accumulated other comprehensive income (loss) components are included in sales or cost of sales and as a component of net periodic pension cost, respectively. Refer to Note 5 and Note 11, respectively, for further details.

Fair Value of Financial Instr_2

Fair Value of Financial Instruments (Tables)	9 Months Ended
	Sep. 30, 2021
Fair Value Disclosures [Abstract]
Schedule of Notional Amounts of Outstanding Derivative Positions	The following table presents the notional contract amounts for forward contracts outstanding: As of FASB ASC Topic 815 Designation September 30, 2021 December 31, 2020 Forward exchange contracts Cash flow hedge $ 178,908 $ 154,504 Forward exchange contracts Non-designated 37,254 42,380
Schedule of Cash Flow Hedges Included in Accumulated Other Comprehensive Income (Loss)	Foreign exchange contracts designated as cash flow hedges had the following effects on accumulated other comprehensive income (loss) ("AOCI") and net earnings on our consolidated condensed statements of comprehensive income (loss) and our consolidated condensed balance sheets: Amount of Gain (Loss) Recognized in AOCI Consolidated Condensed Statements of Comprehensive Income (Loss) Amount of Gain (Loss) Reclassified from AOCI Three Months Ended September 30, Total Amount of Line Item Presented Derivative Instrument 2021 2020 Location of amount reclassified 2021 2020 2021 2020 Foreign exchange contracts $ 3,188 $ (3,542) Net Sales $ 248,827 $ 237,835 $ (1,077) $ 663 Cost of Sales 106,521 104,137 419 (215) Pre-tax gain (loss) $ 3,188 $ (3,542) $ (658) $ 448 Tax expense (benefit) 770 (856) (159) 108 Net gain (loss) $ 2,418 $ (2,686) $ (499) $ 340 Amount of Gain (Loss) Recognized in AOCI Consolidated Condensed Statements of Comprehensive Income (Loss) Amount of Gain (Loss) Reclassified from AOCI Nine Months Ended September 30, Total Amount of Line Item Presented Derivative Instrument 2021 2020 Location of amount reclassified 2021 2020 2021 2020 Foreign exchange contracts $ 6,778 $ (2,526) Net Sales $ 736,665 $ 609,631 $ (4,948) $ 2,206 Cost of Sales 324,485 284,845 1,094 (710) Pre-tax gain (loss) $ 6,778 $ (2,526) $ (3,854) $ 1,496 Tax expense (benefit) 1,637 (610) (931) 362 Net gain (loss) $ 5,141 $ (1,916) $ (2,923) $ 1,134
Derivatives Not Designated as Hedging Instruments	Net losses from derivative instruments not accounted for as hedges and gains and losses on our intercompany receivables on our consolidated condensed statements of comprehensive income (loss) were: Three Months Ended September 30, Nine Months Ended September 30, Derivative Instrument Location on Consolidated Condensed Statements of Comprehensive Income (Loss) 2021 2020 2021 2020 Net loss on currency forward contracts Selling and administrative expense $ (48) $ (682) $ (398) $ (1,224) Net gain (loss) on currency transaction exposures Selling and administrative expense $ (441) $ 312 $ (1,320) $ 143
Schedule of Fair Value for Forward Foreign Exchange Contracts	The following tables summarize the fair value for forward foreign exchange contracts outstanding at September 30, 2021 and December 31, 2020: September 30, 2021 Location on Consolidated Condensed Balance Sheet Asset Fair Value Liabilities Fair Value Net Derivatives designated as hedged instruments: Foreign exchange contracts Prepaid expenses and other current assets $ 3,319 $ (1,311) $ 2,008 Foreign exchange contracts Other long-term assets 932 (145) 787 $ 4,251 $ (1,456) $ 2,795 Derivatives not designated as hedging instruments: Foreign exchange contracts Other current liabilities 21 (160) (139) Total derivatives $ 4,272 $ (1,616) $ 2,656 December 31, 2020 Location on Consolidated Condensed Balance Sheet Asset Fair Value Liabilities Fair Value Net Derivatives designated as hedged instruments: Foreign exchange contracts Other current liabilities $ 1,500 $ (8,826) $ (7,326) Foreign exchange contracts Other long-term liabilities 23 (535) (512) $ 1,523 $ (9,361) $ (7,838) Derivatives not designated as hedging instruments: Foreign exchange contracts Other current liabilities 25 (150) (125) Total derivatives $ 1,548 $ (9,511) $ (7,963)

Inventories (Tables)

Inventories (Tables)	9 Months Ended
	Sep. 30, 2021
Inventory Disclosure [Abstract]
Schedule of inventory	Inventories consist of the following: September 30, December 31, Raw materials $ 76,637 $ 71,807 Work-in-process 17,658 15,864 Finished goods 134,277 107,197 Total $ 228,572 $ 194,868

Earnings (Loss) Per Share (Tabl

Earnings (Loss) Per Share (Tables)	9 Months Ended
	Sep. 30, 2021
Earnings Per Share [Abstract]
Schedule of calculation of basic and diluted earnings (loss) per share	The following table sets forth the computation of basic and diluted earnings (loss) per share for the three and nine months ended September 30, 2021 and 2020: Three Months Ended September 30, Nine Months Ended September 30, 2021 2020 2021 2020 Net income (loss) $ 14,948 $ 6,850 $ 38,098 $ (14,623) Basic – weighted average shares outstanding 29,179 28,583 29,097 28,529 Effect of dilutive potential securities 2,964 843 2,923 — Diluted – weighted average shares outstanding 32,143 29,426 32,020 28,529 Net income (loss) (per share) Basic $ 0.51 $ 0.24 $ 1.31 $ (0.51) Diluted 0.47 0.23 1.19 (0.51)

Goodwill and Other Intangible_2

Goodwill and Other Intangible Assets (Tables)	9 Months Ended
	Sep. 30, 2021
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of Goodwill	The changes in the net carrying amount of goodwill for the nine months ended September 30, 2021 are as follows: Balance as of December 31, 2020 $ 618,440 Foreign currency translation (789) Balance as of September 30, 2021 $ 617,651
Schedule of Finite-Lived Intangible Assets	Other intangible assets consist of the following: September 30, 2021 December 31, 2020 Weighted Average Amortization Period (Years) Gross Accumulated Gross Accumulated Intangible assets with definite lives: 22 Customer and distributor relationships 24 $ 342,501 $ (148,330) $ 342,639 $ (134,555) Sales representation, marketing and promotional rights 25 149,376 (58,500) 149,376 (54,000) Developed technology 16 106,604 (24,801) 106,604 (19,705) Patents and other intangible assets 16 75,836 (50,369) 73,516 (48,882) Intangible assets with indefinite lives: Trademarks and tradenames 86,544 — 86,544 — $ 760,861 $ (282,000) $ 758,679 $ (257,142)
Schedule of Indefinite-Lived Intangible Assets	Other intangible assets consist of the following: September 30, 2021 December 31, 2020 Weighted Average Amortization Period (Years) Gross Accumulated Gross Accumulated Intangible assets with definite lives: 22 Customer and distributor relationships 24 $ 342,501 $ (148,330) $ 342,639 $ (134,555) Sales representation, marketing and promotional rights 25 149,376 (58,500) 149,376 (54,000) Developed technology 16 106,604 (24,801) 106,604 (19,705) Patents and other intangible assets 16 75,836 (50,369) 73,516 (48,882) Intangible assets with indefinite lives: Trademarks and tradenames 86,544 — 86,544 — $ 760,861 $ (282,000) $ 758,679 $ (257,142)
Schedule of Estimated Amortization Expense	The estimated intangible asset amortization expense remaining for the year ending December 31, 2021 and for each of the five succeeding years is as follows: Amortization included in expense Amortization recorded as a reduction of revenue Total Remaining, 2021 $ 7,187 $ 1,500 $ 8,687 2022 26,554 6,000 32,554 2023 25,679 6,000 31,679 2024 24,929 6,000 30,929 2025 25,145 6,000 31,145 2026 24,652 6,000 30,652

Long Term Debt (Tables)

Long Term Debt (Tables)	9 Months Ended
	Sep. 30, 2021
Debt Disclosure [Abstract]
Schedule of Long-term Debt	Long-term debt consists of the following: September 30, 2021 December 31, 2020 Revolving line of credit $ 171,000 $ 207,000 Term loan, net of deferred debt issuance costs of $1,448 and $1,668 in 2021 and 2020, respectively 229,102 240,145 2.625% convertible notes, net of deferred debt issuance costs of $4,144 and $5,475 in 2021 and 2020, respectively, and unamortized discount of $26,009 and $33,620 in 2021 and 2020, respectively 314,846 305,904 Financing leases 638 587 Total debt 715,586 753,636 Less: Current portion 12,251 18,415 Total long-term debt $ 703,335 $ 735,221
Schedule of Maturities of Long-term Debt	The scheduled maturities of long-term debt outstanding at September 30, 2021 are as follows: Remaining 2021 $ 2,981 2022 11,925 2023 14,906 2024 365,869 2025 23,850 2026 327,018 The above amounts exclude debt discount, deferred debt issuance costs and financing leases.

Guarantees (Tables)

Guarantees (Tables)	9 Months Ended
	Sep. 30, 2021
Guarantees [Abstract]
Changes in the carrying amount of service and product warranties	Changes in the liability for standard warranties for the nine months ended September 30, are as follows: 2021 2020 Balance as of January 1, $ 1,826 $ 2,186 Provision for warranties 1,235 616 Claims made (683) (932) Balance as of September 30, $ 2,378 $ 1,870

Pension Plan (Tables)

Pension Plan (Tables)	9 Months Ended
	Sep. 30, 2021
Retirement Benefits [Abstract]
Schedule of net benefit cost	Net periodic pension cost consists of the following: Three Months Ended September 30, Nine Months Ended September 30, 2021 2020 2021 2020 Service cost $ 248 $ 179 $ 744 $ 537 Interest cost on projected benefit obligation 451 639 1,353 1,917 Expected return on plan assets (1,289) (1,255) (3,867) (3,765) Net amortization and deferral 832 705 2,496 2,115 Net periodic pension cost $ 242 $ 268 $ 726 $ 804

Acquisition and Other Expense (

Acquisition and Other Expense (Tables)	9 Months Ended
	Sep. 30, 2021
Acquisition and Other Expense [Abstract]
Schedule of Acquisition and Other Operating Expense	Acquisition and other expense consist of the following, which are included in cost of sales, selling and administrative expense or other expense depending on the nature of the charge: Three Months Ended September 30, Nine Months Ended September 30, 2021 2020 2021 2020 Plant underutilization costs $ — $ — $ — $ 6,586 Product rationalization costs - inventory — — — 2,169 Restructuring costs — — — 1,087 Manufacturing consolidation costs — 606 — 3,993 Acquisition and integration costs — 796 — 2,253 Acquisition and other expense included in cost of sales $ — $ 1,402 $ — $ 16,088 Restructuring and related costs $ — $ 1,009 $ 414 $ 3,133 Product rationalization costs - field inventory — — — 2,095 Acquisition and integration costs — — — 1,192 Acquisition and other expense included in selling and administrative expense $ — $ 1,009 $ 414 $ 6,420 Debt refinancing costs included in other expense $ 1,127 $ — $ 1,127 $ —

Business Segment (Tables)

Business Segment (Tables)	9 Months Ended
	Sep. 30, 2021
Segment Reporting [Abstract]
Schedule of net sales information by product line	These product lines' net sales are as follows: Three Months Ended September 30, Nine Months Ended September 30, 2021 2020 2021 2020 Orthopedic surgery $ 105,751 $ 102,187 $ 320,809 $ 261,954 General surgery 143,076 135,648 415,856 347,677 Consolidated net sales $ 248,827 $ 237,835 $ 736,665 $ 609,631

Revenues (Disaggregated Revenue

Revenues (Disaggregated Revenues) (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Disaggregation of Revenue [Line Items]
Net Sales	$ 248,827	$ 237,835	$ 736,665	$ 609,631
Goods transferred at a point in time
Disaggregation of Revenue [Line Items]
Net Sales	238,187	227,745	704,026	582,292
Services transferred over time
Disaggregation of Revenue [Line Items]
Net Sales	10,640	10,090	32,639	27,339
Orthopedic Surgery
Disaggregation of Revenue [Line Items]
Net Sales	105,751	102,187	320,809	261,954
Orthopedic Surgery | Goods transferred at a point in time
Disaggregation of Revenue [Line Items]
Net Sales	96,389	93,000	291,728	237,224
Orthopedic Surgery | Services transferred over time
Disaggregation of Revenue [Line Items]
Net Sales	9,362	9,187	29,081	24,730
General Surgery
Disaggregation of Revenue [Line Items]
Net Sales	143,076	135,648	415,856	347,677
General Surgery | Goods transferred at a point in time
Disaggregation of Revenue [Line Items]
Net Sales	141,798	134,745	412,298	345,068
General Surgery | Services transferred over time
Disaggregation of Revenue [Line Items]
Net Sales	1,278	903	3,558	2,609
United States
Disaggregation of Revenue [Line Items]
Net Sales	136,401	134,205	403,933	340,476
United States | Orthopedic Surgery
Disaggregation of Revenue [Line Items]
Net Sales	37,957	38,913	115,864	97,339
United States | General Surgery
Disaggregation of Revenue [Line Items]
Net Sales	98,444	95,292	288,069	243,137
Americas (excluding the United States)
Disaggregation of Revenue [Line Items]
Net Sales	24,736	21,134	71,497	55,136
Americas (excluding the United States) | Orthopedic Surgery
Disaggregation of Revenue [Line Items]
Net Sales	16,122	13,767	47,215	35,152
Americas (excluding the United States) | General Surgery
Disaggregation of Revenue [Line Items]
Net Sales	8,614	7,367	24,282	19,984
Europe, Middle East & Africa
Disaggregation of Revenue [Line Items]
Net Sales	44,060	40,688	135,921	113,071
Europe, Middle East & Africa | Orthopedic Surgery
Disaggregation of Revenue [Line Items]
Net Sales	24,155	23,104	77,327	62,726
Europe, Middle East & Africa | General Surgery
Disaggregation of Revenue [Line Items]
Net Sales	19,905	17,584	58,594	50,345
Asia Pacific
Disaggregation of Revenue [Line Items]
Net Sales	43,630	41,808	125,314	100,948
Asia Pacific | Orthopedic Surgery
Disaggregation of Revenue [Line Items]
Net Sales	27,517	26,403	80,403	66,737
Asia Pacific | General Surgery
Disaggregation of Revenue [Line Items]
Net Sales	$ 16,113	$ 15,405	$ 44,911	$ 34,211

Revenues (Customer Liability) (

Revenues (Customer Liability) (Details) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Dec. 31, 2020
Revenue from Contract with Customer [Abstract]
Contract liability	$ 15,833		$ 13,666
Revenue recognized	$ 8,400	$ 7,600

Comprehensive Income (Loss) (De

Comprehensive Income (Loss) (Details) - USD ($) $ in Thousands	3 Months Ended						9 Months Ended
	Sep. 30, 2021	Jun. 30, 2021	Mar. 31, 2021	Sep. 30, 2020	Jun. 30, 2020	Mar. 31, 2020	Sep. 30, 2021	Sep. 30, 2020
Equity [Abstract]
Net income (loss)	$ 14,948			$ 6,850			$ 38,098	$ (14,623)
Cash flow hedging gain (loss), net	2,917			(3,026)			8,064	(3,050)
Pension liability, net of income tax	631			535			1,893	1,605
Foreign currency translation adjustments	(4,740)			4,617			(5,813)	(790)
Comprehensive income (loss)	13,756	$ 17,743	$ 10,743	8,976	$ (24,713)	$ (1,121)	42,242	(16,858)
Pension liability, tax	201			170			603	510
Cash flow hedging gain (loss), tax	$ 929			$ (964)			$ 2,568	$ (972)

Comprehensive Income (Loss) (Ac

Comprehensive Income (Loss) (Accumulated Other Comprehensive Income (Loss)) (Details) - USD ($) $ in Thousands		9 Months Ended
		Sep. 30, 2021	Sep. 30, 2020
Accumulated other comprehensive income (loss) [Roll Forward]
Accumulated Other Comprehensive Income (Loss), Net of Tax		$ (63,681)
Accumulated Other Comprehensive Income (Loss), Net of Tax		(59,537)
Accumulated Other Comprehensive Loss
Accumulated other comprehensive income (loss) [Roll Forward]
Accumulated Other Comprehensive Income (Loss), Net of Tax		(63,681)	$ (59,277)
Other comprehensive income (loss) before reclassifications, net of tax		(672)	(2,706)
Amounts reclassified from other accumulated comprehensive income (loss) before tax	[1]	6,350	619
Reclassification from AOCI, Current Period, Tax		(1,534)	(148)
Net current-period other comprehensive income (loss)		4,144	(2,235)
Accumulated Other Comprehensive Income (Loss), Net of Tax		(59,537)	(61,512)
Cash Flow Hedging Gain (Loss)
Accumulated other comprehensive income (loss) [Roll Forward]
Accumulated Other Comprehensive Income (Loss), Net of Tax		(5,945)	493
Other comprehensive income (loss) before reclassifications, net of tax		5,141	(1,916)
Amounts reclassified from other accumulated comprehensive income (loss) before tax	[1]	3,854	(1,496)
Reclassification from AOCI, Current Period, Tax		(931)	362
Net current-period other comprehensive income (loss)		8,064	(3,050)
Accumulated Other Comprehensive Income (Loss), Net of Tax		2,119	(2,557)
Pension Liability
Accumulated other comprehensive income (loss) [Roll Forward]
Accumulated Other Comprehensive Income (Loss), Net of Tax		(36,620)	(31,691)
Other comprehensive income (loss) before reclassifications, net of tax		0	0
Amounts reclassified from other accumulated comprehensive income (loss) before tax	[1]	2,496	2,115
Reclassification from AOCI, Current Period, Tax		(603)	(510)
Net current-period other comprehensive income (loss)		1,893	1,605
Accumulated Other Comprehensive Income (Loss), Net of Tax		(34,727)	(30,086)
Cumulative Translation Adjustments
Accumulated other comprehensive income (loss) [Roll Forward]
Accumulated Other Comprehensive Income (Loss), Net of Tax		(21,116)	(28,079)
Other comprehensive income (loss) before reclassifications, net of tax		(5,813)	(790)
Amounts reclassified from other accumulated comprehensive income (loss) before tax	[1]	0	0
Reclassification from AOCI, Current Period, Tax		0	0
Net current-period other comprehensive income (loss)		(5,813)	(790)
Accumulated Other Comprehensive Income (Loss), Net of Tax		$ (26,929)	$ (28,869)
[1]	The cash flow hedging gain (loss) and pension liability accumulated other comprehensive income (loss) components are included in sales or cost of sales and as a component of net periodic pension cost, respectively. Refer to Note 5 and Note 11, respectively, for further details.

Fair Value of Financial Instr_3

Fair Value of Financial Instruments (Amounts Recorded In and Reclassified From AOCI) (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Derivative Instruments, Gain (Loss) [Line Items]
Net sales	$ 248,827	$ 237,835	$ 736,665	$ 609,631
Cost of sales	106,521	104,137	324,485	284,845
Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification and Tax	3,188	(3,542)	6,778	(2,526)
Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification, Tax	770	(856)	1,637	(610)
Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification, after Tax	2,418	(2,686)	5,141	(1,916)
Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, before Tax	(658)	448	(3,854)	1,496
Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, Tax	(159)	108	(931)	362
Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, after Tax	(499)	340	(2,923)	1,134
Revenues
Derivative Instruments, Gain (Loss) [Line Items]
Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, before Tax	(1,077)	663	(4,948)	2,206
Cost of Sales
Derivative Instruments, Gain (Loss) [Line Items]
Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, before Tax	$ 419	$ (215)	$ 1,094	$ (710)

Fair Value of Financial Instr_4

Fair Value of Financial Instruments (Foreign Currency Forward Contracts) (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020	Dec. 31, 2020
Derivative [Line Items]
Foreign Currency Transaction Gain (Loss), before Tax	$ (441)	$ 312	$ (1,320)	$ 143
Derivative Assets and Liabilities at Fair Value [Abstract]
Asset Fair Value	4,272		4,272		$ 1,548
Liabilities Fair Value	(1,616)		(1,616)		(9,511)
Net Fair Value	2,656		2,656		(7,963)
Foreign Currency Forward Contracts
Derivative [Line Items]
Gain (Loss) on Foreign Currency Derivative Instruments Not Designated as Hedging Instruments	(48)	$ (682)	(398)	$ (1,224)
Derivatives designated as hedged instruments: | Foreign Currency Forward Contracts
Derivative Assets and Liabilities at Fair Value [Abstract]
Asset Fair Value	4,251		4,251		1,523
Liabilities Fair Value	(1,456)		(1,456)		(9,361)
Net Fair Value	2,795		2,795		(7,838)
Derivatives designated as hedged instruments: | Foreign Currency Forward Contracts | Prepaid Expenses and Other Current Assets [Member]
Derivative Assets and Liabilities at Fair Value [Abstract]
Asset Fair Value	3,319		3,319
Liabilities Fair Value	(1,311)		(1,311)
Net Fair Value	2,008		2,008
Derivatives designated as hedged instruments: | Foreign Currency Forward Contracts | Other Noncurrent Liabilities [Member]
Derivative Assets and Liabilities at Fair Value [Abstract]
Asset Fair Value					23
Liabilities Fair Value					(535)
Net Fair Value					(512)
Derivatives designated as hedged instruments: | Foreign Currency Forward Contracts | Other Current Liabilities [Member]
Derivative Assets and Liabilities at Fair Value [Abstract]
Asset Fair Value					1,500
Liabilities Fair Value					(8,826)
Net Fair Value					(7,326)
Derivatives designated as hedged instruments: | Foreign Currency Forward Contracts | Other Noncurrent Assets [Member]
Derivative Assets and Liabilities at Fair Value [Abstract]
Asset Fair Value	932		932
Liabilities Fair Value	(145)		(145)
Net Fair Value	787		$ 787
Derivatives not designated as hedging instruments: | Foreign Currency Forward Contracts
Derivative [Line Items]
Maximum Length of Time Hedged in Cash Flow Hedge			1 month
Notional amount of cash flow hedges	37,254		$ 37,254		42,380
Derivatives not designated as hedging instruments: | Foreign Currency Forward Contracts | Other Current Liabilities [Member]
Derivative Assets and Liabilities at Fair Value [Abstract]
Asset Fair Value	21		21		25
Liabilities Fair Value	(160)		(160)		(150)
Net Fair Value	(139)		$ (139)		(125)
Cash flow hedge | Foreign Currency Forward Contracts
Derivative [Line Items]
Maximum Length of Time Hedged in Cash Flow Hedge			2 years
Notional amount of cash flow hedges	178,908		$ 178,908		$ 154,504
Foreign Currency Cash Flow Hedge Gain (Loss) to be Reclassified During Next 12 Months	$ 1,500		$ 1,500

Inventories (Details)

Inventories (Details) - USD ($) $ in Thousands	Sep. 30, 2021	Dec. 31, 2020
Inventory Disclosure [Abstract]
Raw materials	$ 76,637	$ 71,807
Work-in-process	17,658	15,864
Finished goods	134,277	107,197
Total inventory	$ 228,572	$ 194,868

Earnings (Loss) Per Share (Deta

Earnings (Loss) Per Share (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Earnings Per Share [Abstract]
Net income (loss)	$ 14,948	$ 6,850	$ 38,098	$ (14,623)
Basic-weighted average shares outstanding (in shares)	29,179	28,583	29,097	28,529
Effect of dilutive potential securities (in shares)	2,964	843	2,923	0
Diluted- weighted average shares outstanding (in shares)	32,143	29,426	32,020	28,529
Basic (in dollars per share)	$ 0.51	$ 0.24	$ 1.31	$ (0.51)
Diluted (in dollars per share)	$ 0.47	$ 0.23	$ 1.19	$ (0.51)
Antidilutive securities excluded from computation of earnings per share (in shares)	700	1,600	500
Incremental Common Shares Attributable to Dilutive Effect of Conversion of Debt Securities	1,200		1,200
Incremental Common Shares Attributable to Dilutive Effect of Warrants	500		400

Earnings (Loss) Per Share - Con

Earnings (Loss) Per Share - Convertible Notes (Details) - Convertible Notes Payable - 2.625 Percent Convertible Notes Due 2024 [Member]	Jan. 29, 2019$ / shares
Debt Instrument [Line Items]
Interest rate, stated percentage	2.625%
Conversion price (in dollars per share)	$ 88.80
Hedge transactions
Debt Instrument [Line Items]
Option indexed to issuer's equity, strike price (in dollars per share)	114.92
Warrant
Debt Instrument [Line Items]
Option indexed to issuer's equity, strike price (in dollars per share)	$ 114.92

Goodwill and Other Intangible_3

Goodwill and Other Intangible Assets (Goodwill) (Details) $ in Thousands	9 Months Ended
	Sep. 30, 2021USD ($)
Goodwill [Roll Forward]
Beginning balance	$ 618,440
Foreign currency translation	(789)
Ending balance	$ 617,651

Goodwill and Other Intangible_4

Goodwill and Other Intangible Assets (Intangible Assets) (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020	Dec. 31, 2020
Schedule of Finite-Lived and Indefinite-Lived Assets [Line Items]
Intangible assets, Gross carrying amount	$ 760,861		$ 760,861		$ 758,679
Intangible assets, Accumulated amortization	(282,000)		(282,000)		(257,142)
Amortization expense	8,300	$ 8,600	24,900	$ 25,600
Payments for Contingent Consideration			3,536	$ 2,071
Future amortization expense [Abstract]
Remaining, 2021	8,687		8,687
2022	32,554		32,554
2023	31,679		31,679
2024	30,929		30,929
2025	31,145		31,145
2026	30,652		30,652
Amortization included in expense
Future amortization expense [Abstract]
Remaining, 2021	7,187		7,187
2022	26,554		26,554
2023	25,679		25,679
2024	24,929		24,929
2025	25,145		25,145
2026	24,652		24,652
Amortization recorded as a reduction of revenue
Future amortization expense [Abstract]
Remaining, 2021	1,500		1,500
2022	6,000		6,000
2023	6,000		6,000
2024	6,000		6,000
2025	6,000		6,000
2026	6,000		6,000
Trademarks & tradenames
Schedule of Finite-Lived and Indefinite-Lived Assets [Line Items]
Unamortized intangible assets, Gross carrying amount	86,544		86,544		86,544
Customer and distributor relationships
Schedule of Finite-Lived and Indefinite-Lived Assets [Line Items]
Amortized intangible assets, Gross carrying amount	342,501		342,501		342,639
Intangible assets, Accumulated amortization	(148,330)		(148,330)		(134,555)
Sales representation, marketing and promotional rights
Schedule of Finite-Lived and Indefinite-Lived Assets [Line Items]
Amortized intangible assets, Gross carrying amount	149,376		149,376		149,376
Intangible assets, Accumulated amortization	(58,500)		(58,500)		(54,000)
Patents and other intangible assets
Schedule of Finite-Lived and Indefinite-Lived Assets [Line Items]
Amortized intangible assets, Gross carrying amount	75,836		75,836		73,516
Intangible assets, Accumulated amortization	(50,369)		(50,369)		(48,882)
Developed technology
Schedule of Finite-Lived and Indefinite-Lived Assets [Line Items]
Amortized intangible assets, Gross carrying amount	106,604		106,604		106,604
Intangible assets, Accumulated amortization	(24,801)		(24,801)		$ (19,705)
Payments for Contingent Consideration	3,500		3,500
Asset acquisition, contingent consideration liability	$ 2,400		$ 2,400
Weighted Average
Schedule of Finite-Lived and Indefinite-Lived Assets [Line Items]
Finite-lived intangible asset useful life (in years)			22 years
Weighted Average | Customer and distributor relationships
Schedule of Finite-Lived and Indefinite-Lived Assets [Line Items]
Finite-lived intangible asset useful life (in years)			24 years
Weighted Average | Sales representation, marketing and promotional rights
Schedule of Finite-Lived and Indefinite-Lived Assets [Line Items]
Finite-lived intangible asset useful life (in years)			25 years
Weighted Average | Patents and other intangible assets
Schedule of Finite-Lived and Indefinite-Lived Assets [Line Items]
Finite-lived intangible asset useful life (in years)			16 years
Weighted Average | Developed technology
Schedule of Finite-Lived and Indefinite-Lived Assets [Line Items]
Finite-lived intangible asset useful life (in years)			16 years

Long Term Debt (Details)

Long Term Debt (Details) - USD ($) $ in Thousands	Sep. 30, 2021	Dec. 31, 2020
Debt Instrument [Line Items]
Long-term Debt and Lease Obligation, Including Current Maturities	$ 715,586	$ 753,636
Finance Lease, Liability	638	587
Current portion of long-term debt	12,251	18,415
Long-term debt	703,335	735,221
Line of Credit [Member]
Debt Instrument [Line Items]
Long-term Debt	171,000	207,000
Term Loan Facility [Member]
Debt Instrument [Line Items]
Long-term Debt	229,102	240,145
Unamortized Debt Issuance Expense	1,448	1,668
Convertible Notes Payable [Member]
Debt Instrument [Line Items]
Convertible Debt	314,846	305,904
Debt Instrument, Unamortized Discount	26,009	33,620
Unamortized Debt Issuance Expense	$ 4,144	$ 5,475

Long Term Debt Additional Infor

Long Term Debt Additional Information (Details)	Jan. 29, 2019USD ($)$ / shares	Sep. 30, 2021USD ($)	Sep. 30, 2020USD ($)	Sep. 30, 2021USD ($)	Sep. 30, 2020USD ($)	Jul. 16, 2021USD ($)	Dec. 31, 2020USD ($)
Debt Instrument [Line Items]
Amortization of debt discount				$ 7,611,000	$ 7,239,000
Term Loan Facility [Member]
Debt Instrument [Line Items]
Long-term Debt, Gross		$ 230,500,000		230,500,000
Long-term Debt		229,102,000		229,102,000			$ 240,145,000
Term Loan Facility [Member] | Amended and Restated Senior Credit Agreement [Member]
Debt Instrument [Line Items]
Debt Instrument, Face Amount						$ 233,500,000
Line of Credit [Member]
Debt Instrument [Line Items]
Long-term Debt		171,000,000		171,000,000			$ 207,000,000
Line of Credit Facility, Remaining Borrowing Capacity		411,500,000		411,500,000
Letters of Credit Outstanding, Amount		2,500,000		2,500,000
Line of Credit [Member] | Amended and Restated Senior Credit Agreement [Member]
Debt Instrument [Line Items]
Line of Credit Facility, Maximum Borrowing Capacity						$ 585,000,000
Convertible Notes Payable [Member] | 2.625 Percent Convertible Notes Due 2024 [Member]
Debt Instrument [Line Items]
Debt Instrument, Face Amount	$ 345,000,000
Debt Instrument, Convertible, Carrying Amount of Equity Component	$ 39,100,000
Amortization of debt discount		2,600,000	$ 2,400,000	7,600,000	7,200,000
Interest rate, stated percentage	2.625%
Debt Instrument, Interest Rate, Effective Percentage	6.14%
Interest Expense, Debt		$ 2,300,000	$ 2,300,000	$ 6,800,000	$ 6,800,000
Debt Instrument, Convertible, Gross Amount of Equity Component	$ 51,600,000
Conversion price (in dollars per share) | $ / shares	$ 88.80
Debt Instrument, Convertible, Conversion Ratio	11.2608
Convertible Notes Payable [Member] | 2.625 Percent Convertible Notes Due 2024 [Member] | Warrant
Debt Instrument [Line Items]
Option indexed to issuer's equity, strike price (in dollars per share) | $ / shares	$ 114.92
Long-term Debt [Member] | Amended and Restated Senior Credit Agreement [Member]
Debt Instrument [Line Items]
Debt Instrument, Interest Rate, Effective Percentage		1.625%		1.625%
LIBOR Interest Rate Floor				0.125%
Long-term Debt [Member] | Amended and Restated Senior Credit Agreement [Member] | London Interbank Offered Rate (LIBOR) [Member]
Debt Instrument [Line Items]
Debt Instrument, Basis Spread on Variable Rate				1.50%
Long-term Debt [Member] | Amended and Restated Senior Credit Agreement [Member] | Adjusted LIBOR
Debt Instrument [Line Items]
Debt Instrument, Basis Spread on Variable Rate				1.00%
Long-term Debt [Member] | Amended and Restated Senior Credit Agreement [Member] | Fed Funds Effective Rate Overnight Index Swap Rate [Member]
Debt Instrument [Line Items]
Line of Credit Facility, Commitment Fee Percentage				0.50%
Call Option [Member] | Convertible Notes Payable [Member] | 2.625 Percent Convertible Notes Due 2024 [Member]
Debt Instrument [Line Items]
Hedge and warrant transactions, net cash paid	$ 21,000,000

Long Term Debt Maturities of Lo

Long Term Debt Maturities of Long Term Debt (Details) $ in Thousands	Sep. 30, 2021USD ($)
Maturities of Long-term Debt [Abstract]
Remaining, 2021	$ 2,981
2022	11,925
2023	14,906
2024	365,869
2025	23,850
2026	$ 327,018

Guarantees (Details)

Guarantees (Details) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020
Guarantees [Abstract]
Standard warranty period (in years)	1 year
Movement in Standard Product Warranty Accrual [Roll Forward]
Balance as of January 1,	$ 1,826	$ 2,186
Provision for warranties	1,235	616
Claims made	(683)	(932)
Balance as of September 30,	2,378	1,870
Extended Product Warranty Disclosure [Abstract]
Product extended warranty expense	$ 5,200	$ 4,400

Pension Plan (Details)

Pension Plan (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Retirement Benefits [Abstract]
Service cost	$ 248	$ 179	$ 744	$ 537
Interest cost on projected benefit obligation	451	639	1,353	1,917
Expected return on plan assets	(1,289)	(1,255)	(3,867)	(3,765)
Net amortization and deferral	832	705	2,496	2,115
Net periodic pension cost	$ 242	268	$ 726	804
Defined Benefit Plan, Non-service cost		$ 100		$ 300

Acquisition and Other Expense_2

Acquisition and Other Expense (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Acquisition and Other Expense [Line Items]
Other expense	$ 1,127	$ 89	$ 1,127	$ 266
Cost of Sales
Acquisition and Other Expense [Line Items]
Plant underutilization cost	0	0	0	6,586
Product rationalization costs - inventory	0	0	0	2,169
Restructuring costs	0	0	0	1,087
Manufacturing consolidation costs	0	606	0	3,993
Acquisition and integration costs	0	796	0	2,253
Acquisition and other expense	0	1,402	0	16,088
Selling and Administrative Expenses
Acquisition and Other Expense [Line Items]
Restucturing and related costs	0	1,009	414	3,133
Product rationalization costs - field inventory	0	0	0	2,095
Acquisition and integration costs	0	0	0	1,192
Acquisition and other expense	0	1,009	414	6,420
Selling and Administrative Expenses | Special Termination Benefits [Member]
Acquisition and Other Expense [Line Items]
Restucturing and related costs				800
Selling and Administrative Expenses | Contract Termination [Member]
Acquisition and Other Expense [Line Items]
Restucturing and related costs		1,000		2,300
Other Expense
Acquisition and Other Expense [Line Items]
Other expense	$ 1,127	$ 0	$ 1,127	$ 0

Business Segment (Details)

Business Segment (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Segment Reporting Information [Line Items]
Net sales	$ 248,827	$ 237,835	$ 736,665	$ 609,631
Orthopedic Surgery
Segment Reporting Information [Line Items]
Net sales	105,751	102,187	320,809	261,954
General Surgery
Segment Reporting Information [Line Items]
Net sales	$ 143,076	$ 135,648	$ 415,856	$ 347,677

Legal Proceedings (Details)

Legal Proceedings (Details) - USD ($) $ in Millions	Jan. 18, 2017	Sep. 30, 2021
Loss Contingencies [Line Items]
Product liability insurance, amount per incident		$ 35
Product liability insurance, aggregate annual amount		$ 35
Pending Litigation | EndoDynamix, Inc. | Liquidated Damages
Loss Contingencies [Line Items]
Loss Contingency, Damages Sought, Value	$ 12.7
Pending Litigation | EndoDynamix, Inc. | Additional Damages
Loss Contingencies [Line Items]
Loss Contingency, Damages Sought, Value	$ 24.8